| In millions, except per share items | Dec-31-09 | Dec-31-08 | Dec-31-07 | Dec-31-06 | Sep-30-06 | Dec-31-05 | Dec-31-04 | Dec-31-03 |
| | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K |
| Revenues: |
| Genomics Services | | | | | 24.3 | | 52.2 | 52.0 |
| Drug Repositioning Services | | | | | 0.0 | | | |
| Other | | | | | | | | 17.6 |
| Total revenues [+] | 0.2 | 2.0 | 11.9 | 8.4 | 24.3 | 6.6 | 52.2 | 69.5 |
| Royalties | 2.5 | 9.7 | 10.3 | 8.4 | 9.9 | 6.6 | 2.4 | 2.1 |
| Services | | | 1.6 | | | | | |
| Revenue growth [+] | -91.0% | -83.6% | 41.1% | 28.3% | | -87.4% | -25.0% | 26.7% |
| Genomics Services | | | | | | | 0.4% | |
| Cost of goods sold | 2.5 | 9.8 | 10.3 | 8.4 | 42.5 | 6.6 | 44.3 | 67.6 |
| Gross profit | -2.3 | -7.9 | 1.6 | 0.0 | -18.2 | 0.0 | 7.9 | 2.0 |
| Gross margin | -1310.9% | -403.7% | 13.5% | 0.0% | -74.7% | 0.0% | 15.1% | 2.8% |
| Selling, general and administrative | 7.2 | 12.7 | 11.1 | 12.2 | 22.4 | 13.2 | 19.2 | 22.2 |
| Research and development | | | | | | | | |
| Equity in earnings | 0.6 | -3.0 | | | | | | |
| Other operating expenses | | | 10.3 | 8.4 | | 6.0 | | |
| EBITDA [+] | -8.8 | -22.5 | -18.7 | -19.3 | | -18.2 | 1.9 | -3.5 |
| EBITDA growth | -61.0% | 20.9% | -3.2% | 6.1% | | -1051.4% | -155.2% | -70.3% |
| EBITDA margin | -5020.6% | -1156.3% | -157.3% | -229.3% | -166.8% | -277.2% | 3.7% | -5.0% |
| Depreciation and amortization | 0.1 | 1.0 | 1.1 | 1.3 | | 1.0 | 13.3 | 16.8 |
| EBIT [+] | -8.9 | -23.5 | -19.8 | -20.5 | -40.6 | -19.1 | -11.4 | -20.2 |
| EBIT growth | -62.2% | 19.0% | -3.7% | 7.4% | | 68.2% | -43.8% | -19.7% |
| EBIT margin | -5082.9% | -1206.3% | -166.7% | -244.4% | -166.8% | -291.9% | -21.8% | -29.1% |
| Non-recurring items [+] | | -0.1 | | | | | 8.8 | |
| Loss (gain) on sale of assets | | -0.1 | | | | | | |
| In-process research & development | | | | | | | 8.8 | |
| Interest expense, net [+] | -0.5 | -0.8 | 2.0 | 2.7 | | 2.6 | 1.4 | 1.7 |
| Interest expense | | | 2.0 | 2.7 | | 2.6 | 1.4 | 1.7 |
| Interest income | 0.5 | 0.8 | | | | | | |
| Other income (expense), net | | 0.1 | 4.0 | 5.1 | 2.4 | 4.5 | 2.8 | -0.6 |
| Pre-tax income | -8.4 | -22.5 | -17.8 | -18.1 | -38.3 | -17.2 | -18.8 | -22.5 |
| Income taxes | 0.0 | 0.0 | 16.9 | 36.6 | 0.0 | 31.1 | 0.3 | 2.2 |
| Tax rate | 0.0% | 0.0% | | | 0.0% | | | |
| Net income | -8.4 | -22.5 | -34.7 | -54.7 | -54.7 | -48.3 | -28.5 | -24.8 |
| Net margin | -4790.3% | -1151.8% | -292.6% | -651.1% | -224.7% | -737.2% | -54.7% | -35.6% |
| |
| Basic EPS [+] | ($1.53) | ($3.97) | ($5.44) | ($1.72) | ($1.20) | ($1.52) | ($0.61) | ($0.82) |
| Growth | -61.4% | -27.1% | 216.3% | 13.0% | | 151.2% | -26.3% | -7.8% |
| Diluted EPS [+] | ($1.53) | ($3.97) | ($5.44) | ($1.72) | ($1.20) | ($1.52) | ($0.61) | ($0.82) |
| Growth | -61.4% | -27.1% | 216.3% | 13.0% | | 151.2% | -26.3% | -7.8% |
| |
| Shares outstanding (basic) [+] | 5.5 | 5.7 | 6.4 | 31.8 | 31.8 | 31.7 | 31.5 | 30.1 |
| Growth | -3.3% | -11.2% | -80.0% | 0.2% | | 0.8% | 4.6% | 11.7% |
| Shares outstanding (diluted) [+] | 5.5 | 5.7 | 6.4 | 31.8 | 31.8 | 31.7 | 31.5 | 30.1 |
| Growth | -3.3% | -11.2% | -80.0% | 0.2% | | 0.8% | 4.6% | 11.7% |
| |
| EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |